Avista picks up OTC drug developer Wellspring from Audax

‘The diversified and highly established nature of WellSpring’s product portfolio, coupled with a strong innovation pipeline and exciting growth opportunities in e-commerce, was very compelling,’ said Avista’s Yu.

23 August 2022•2 mins read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles